(Q36198648)

12 August 2017

1 reference

title

Clinical experience with therapeutic AIDS vaccines (English)

1 reference

12 August 2017

Aldar S Bourinbaiar

1

1 reference

12 August 2017

Rivka Abulafia-Lapid

series ordinal

2

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Expert Review of Vaccines

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

289-304

1 reference

12 August 2017

cites work

Therapeutic HIV Vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Therapeutic vaccination against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

DNA mucosal HIV vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Inhibitory effect of natural interferon alpha on human immunodeficiency virus type 1 transmission from epithelial cells to lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Attempts to cure and prevent HIV/AIDS in central Nigeria between 1997 and 2002: opening a way to a vaccine-based solution to the problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Jerimiah Abalaka and HIV in Nigeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Editorial and report by J.O.A. Abalaka. "Attempts to cure and prevent HIV/AIDS in Central Nigeria between 1997 and 2002: opening a way to a vaccine-based solution to the problem".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Therapeutic vaccination for future management of HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Enhanced cellular immunity in macaques following a novel peptide immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

The immune response to AIDS virus infection: good, bad, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Characterization of high-risk HIV-1 seronegative hemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

An idiotypic network model of AIDS immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Alloimmunization as a strategy for vaccine design against HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

The Trojan exosome hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Immunologic Mechanisms and Therapy in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Therapeutic vaccines in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

T-cell vaccination for autoimmune disease: a panorama

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Oral immune regulation: a novel method for modulation of anti-viral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

21 January 2018

Mucosal AIDS vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Alloimmunization as an AIDS vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

Anti-cell antibody in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.289

21 January 2018

Identifiers

DOI

10.1586/14760584.4.3.289

1 reference

12 August 2017

1 reference